The Predictive Value of Pre-plus Disease in ROP
The Predictive Value of Pre-plus Disease in ROP
批准号:
7473815
负责人:
DAVID K WALLACE
金额:
$26.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2010-07-31
关键词:
AddressAgeApplications GrantsBedsBiometryBlindnessBlood VesselsChildChildhoodClassificationClinicalClinical TrialsCold TherapyCommunicationConduct Clinical TrialsCounselingDataDescriptorDevelopmentDiagnosisDiseaseDisease ProgressionEligibility DeterminationEnsureEpidemiologyEyeEye diseasesImageIncidenceInfantInternationalInterventionLasersLeadLearningLocationLow-Level Laser TherapyMasksMaster&aposs DegreeMedical EthicsMentored Clinical Oncology AwardMentored Clinical Scientist AwardMentored Patient-Oriented Research Career Development AwardMinorMulti-Institutional Clinical TrialNatural HistoryNeonatal Intensive Care UnitsNorth CarolinaOphthalmologyOphthalmoscopyParentsPatientsPediatric HospitalsPredictive ValuePremature InfantProbabilityPrognostic FactorPublic HealthResearch DesignResearch PersonnelResearch Project GrantsRetinalRetinal DetachmentRetinopathy of PrematurityRiskScreening procedureSeveritiesSeverity of illnessStagingStandards of Weights and MeasuresStatistical Data InterpretationStatistical MethodsSupervisionTestingUnited StatesUniversitiesVenousVisionVisualVisual impairmentWeekWorkclinical Diagnosiscohortdigitalexperienceimprovedoutcome forecastpatient oriented researchpreventprognosticprotocol developmentretina blood vessel structureskills trainingtime interval
中文摘要
描述(由申请人提供):该K23奖将允许候选人获得必要的培训和技能,以开发和领导儿童眼科以患者为导向的研究项目,包括多中心临床试验。候选人将学习研究设计、方案开发、拨款申请、项目管理、数据分析、统计方法、结果沟通和医学伦理。为了实现这些目标,候选人将(1)在Roy Beck博士的直接指导下参与儿科眼病调查员小组进行的多项临床试验,(2)获得公共卫生硕士学位,主修流行病学,辅修生物统计学,(3)在Graham Quinn博士的指导下完成一项关于早产儿视网膜病变(ROP)的研究项目,ROP是美国儿童失明的主要原因之一。拟议的研究项目将利用数字视网膜图像来验证我们的假设,即患有pre-plus疾病(轻度至中度异常血管扩张和视网膜中央、后血管扭曲)的眼睛更容易发生威胁视力的ROP。具体目的是:(1)调查pre-plus是否能预测严重ROP(阈值疾病)的进展,(2)确定pre-plus是否在已建立的ROP位置(区域)和严重程度(阶段)描述符提供的预测价值之外增加了预测价值,以及(3)研究pre-plus疾病的自然史。为了解决这些问题,两位蒙面ROP专家将对150名婴儿的间接视镜视频生成的数字视网膜图像中的血管扩张和扭曲程度进行分级。pre-plus的眼睛将与正常的眼睛进行比较,比较其进展到阈值的比例。如果pre-plus能准确预测进展到阈值,则具有重要的临床意义。这些措施包括提高识别高危婴儿的能力,这些婴儿可能受益于比常规激光治疗更早的治疗,对一些婴儿更有效的筛查方案,以及更准确地向父母提供有关疾病进展风险的咨询。
英文摘要
DESCRIPTION (provided by applicant): This K23 Award will allow the candidate to obtain the training and skills necessary to develop and lead patient-oriented research projects in pediatric ophthalmology, including multi-center clinical trials. The candidate will learn study design, protocol development, grant application, project management, data analysis, statistical methods, communication of results, and medical ethics. To achieve these objectives, the candidate will (1) work under the direct supervision of Dr. Roy Beck on several clinical trials conducted by the Pediatric Eye Disease Investigator Group, (2) obtain a masters degree in public health with a concentration in epidemiology and a minor in biostatistics, and (3) complete a research project with the guidance of Dr. Graham Quinn in retinopathy of prematurity (ROP), one of the leading causes of childhood blindness in the United States. The proposed research project will utilize digital retinal images to test our hypothesis that eyes with pre-plus disease (mild to moderately abnormal vascular dilation and tortuosity of central, posterior retinal blood vessels) are more likely to develop sight-threatening ROP. The specific aims are (1) to investigate whether pre-plus predicts progression to severe ROP (threshold disease), (2) to determine if pre-plus adds predictive value beyond that already provided by established ROP descriptors of location (zone) and severity (stage), and (3) to study the natural history of pre-plus disease. To address these aims, 2 masked experts in ROP will grade the degree of vascular dilation and tortuosity in digital retinal images generated from video indirect ophthalmoscopy in a cohort of 150 infants. Eyes with pre-plus will be compared to normal eyes in regard to the proportion that progress to threshold. There are important clinical implications if pre-plus accurately predicts progression to threshold. These include improved ability to identify high-risk infants who may benefit from earlier than usual laser treatment, more effective screening protocols for some infants, and more accurate counseling of parents regarding the risk of disease progression.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI:
--
发表时间:
2007
期刊:
Transactions of the American Ophthalmological Society
影响因子:
--
作者:
[D. Wallace]
通讯作者:
D. Wallace
Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels.
目标氧饱和度水平适度降低之前和之后早产儿严重视网膜病变的发生率。
DOI:
10.1016/j.jaapos.2006.08.012
发表时间:
2007
期刊:
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
影响因子:
--
作者:
[Wallace,DavidK, Veness-Meehan,KathleenA, Miller,WilliamC]
通讯作者:
Miller,WilliamC
DOI:
10.1016/mpa.2003.s1091853102000150
发表时间:
2003
期刊:
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
影响因子:
--
作者:
[Wallace,DavidK, Jomier,Julien, Aylward,StevenR, Landers3rd,MauriceB]
通讯作者:
Landers3rd,MauriceB
PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE
-
批准号:9211330
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2014
-
负责人:DAVID K WALLACE
-
依托单位:
PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE
-
批准号:8998949
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2014
-
负责人:DAVID K WALLACE
-
依托单位:
PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE
-
批准号:8474330
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2014
-
负责人:DAVID K WALLACE
-
依托单位:
The Predictive Value of Pre-plus Disease in ROP
-
批准号:7110951
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2004
-
负责人:DAVID K WALLACE
-
依托单位:
The Predictive Value of Pre-plus Disease in ROP
-
批准号:6815294
-
项目类别:
-
资助金额:$27.78万
-
财政年份:2004
-
负责人:DAVID K WALLACE
-
依托单位:
The Predictive Value of Pre-plus Disease in ROP
-
批准号:6930585
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2004
-
负责人:DAVID K WALLACE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: